NIH Locks Doors on Boring Grant Review Meetings

2026-06501 — Government-Owned Inventions; Availability for Licensing

The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.

2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration

The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!

2026-05957 — Center for Scientific Review; Notice of Closed Meetings

The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.

2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.

2026-05673 — Center for Scientific Review; Notice of Closed Meetings

The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.

2026-05738 — Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)

The NIH is asking for a 30-day public comment on extending its Loan Repayment Programs that help doctors and scientists pay off their student loans while they do important health research. This extension keeps the program running smoothly with no big changes, and comments are due by April 23, 2026. If you’re a researcher with student loans, this program could save you money while you help improve health!

Previous: 2026-05524 — NorthWestern Corporation; Notice of Application for Non-Capacity Amendment of License Accepted for Filing and Soliciting Comments, Motions To Intervene, and Protests

NorthWestern Corporation wants to make some changes to its Thompson Falls Hydroelectric Project in Montana, but these changes won’t affect how much power it produces. The government is asking the public and agencies to share their thoughts by April 16, 2026. This is a chance for folks to weigh in before any final decisions are made—no big money or power shifts, just updates to the license.

Next: 2026-05527 — Government-Owned Inventions; Availability for Licensing

The National Institutes of Health is offering a cool new gene-editing invention that can fix a rare genetic disease called ROSAH syndrome, which causes vision loss and other problems. Companies can license this technology to develop treatments that might restore vision and improve lives. Interested parties should act soon and be ready to sign a confidentiality agreement to get all the details.